Japan Pricing Environment ‘Highly Unpredictable’: PhRMA
Holistic Reforms Would 'Create Space'
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
You may also be interested in...
European industry federation says first practical application of Japan’s cost effectiveness assessment system has highlighted a number of problems for both the scheme and its members, and calls for changes.
Despite having multiple world-class pharma companies and innovative research, Japan is notably absent as a source of candidate vaccines for the coronavirus. The pandemic is again throwing into sharp relief past and present challenges around the country's vaccines sector.
Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.